Atara Biotherapeutics Reports Q2 Financial Results, Resumes Strategic Options Evaluation

Atara Biotherapeutics reported Q2 financial results, with cash, cash equivalents, and short-term investments totaling $22.3 million. The company transferred operational activities related to tab-cel to Pierre Fabre Laboratories and resumed its evaluation of strategic options. The FDA has accepted Atara's Biologics License Application for tabelecleucel (tab-cel) for post-transplant lymphoproliferative disease, with a PDUFA target action date of January 10, 2026. Approval would unlock a $40 million milestone payment from Pierre Fabre Laboratories, extending Atara's cash runway.